Retrospective Study of Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jul 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at invasive fungal infections caused by certain types of fungi in patients who have received heart transplants. These infections can be serious, especially for people with weakened immune systems, like those who have had organ transplants. The study aims to gather recent information about how common these infections are, what factors might increase the risk of getting them, and how they affect the health of heart transplant patients. This information can help doctors improve the way they manage these dangerous infections.
To be eligible for the study, participants need to be at least 18 years old, have had a heart transplant, and have experienced a specific type of invasive fungal infection between January 1, 2008, and December 31, 2022. The types of infections being studied include aspergillosis, mucormycosis, fusarium wilt, and others. Participants will not have to do anything extra beyond sharing their medical data, as the study is retrospective, meaning it looks back at past cases. It's important for potential participants to know that their data will be used only for research purposes unless they choose not to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient ≥18 years old
- • Heart transplant
- • Invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022
- * Proven or probable infection with filamentous fungi according to EORTC/MSGERC criteria (20):
- • Invasive aspergillosis
- • Mucormycosis
- • Fusarium wilt
- • Scedosporiosis
- • Other filamentous fungus infection
- • Subject who has not expressed, after information, his opposition to the reuse of his data for the purposes of this research.
- Exclusion Criteria:
- • Patient having expressed his opposition to participating in the study
- • Patient not having a liver transplant
- • Subject under guardianship, curatorship or safeguard of justice.
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported